ORMP

Partnership or licensing announcement (business development) • 2026-06-30

Bear case assumes failed pivotal readouts or inability to commercialize the platform without dilutive financing, returning the equity toward prior lows and steep downside (~45–55%).

Break below $2 or thesis failure.

Bull case assumes positive clinical/regulatory outcomes and at least one commercial partnership that validates the oral-protein delivery platform and materially expands addressable market, justifying a significant multiple re-rate and >70% upside from the anchor. Reviewer note: recent aggregator snippets show consensus targets near $3.25–3.32 (sanity check vs. anchor); bull upside is driven by successful de-risking and BD outcomes within a 12-month window that supports a higher short-to-mid term re-rate [#SERP-1][#SERP-2].